Lepu Biopharma (HKG:2157) said results from its Phase IIb study of MRG003, an antibody drug conjugate for treating recurrent or metastatic nasopharyngeal cancer, were selected as a late-breaking abstract for oral presentation at the 2025 American Society of Clinical Oncology Annual Meeting, according to a Thursday filing on the Hong Kong Exchange.
MRG003 targets epidermal growth factor receptor (EGFR), which is highly expressed in various cancers, including colorectal, lung, and head and neck cancers, and 89% of advanced nasopharyngeal cancer cases.
The drug combines an EGFR-targeted monoclonal antibody with a microtubulin inhibitor payload, designed to kill tumor cells after internalization.
Lepu cautioned there is no assurance that MRG003 will be successfully developed and marketed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.